Compare Amgen, Inc. (AMGN) vs Badger Meter Inc (BMI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Badger Meter Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Badger Meter Inc trades at $144.01 (market cap $4.21B). The key difference: Amgen, Inc. is far larger — about 46.6× Badger Meter Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | BMI | |
|---|---|---|
Market Cap | $196.12B | $4.21B |
Sector | Health | Technology |
52-Week High | $388.16 | $245.81 |
52-Week Low | $271.18 | $113.41 |
Enterprise Value | $241.41B | $4.00B |
Dividend Yield | 2.77% | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Badger Meter (BMI) trades at $144.18, down 0.54% today, with a bullish technical outlook supported by moving averages and strong ADX readings. The company maintains solid profitability with 14.56% net margin and 19.6% ROE, though recent earnings misses and a securities class action lawsuit create near-term uncertainty. Revenue declined to $897M in 2026 from $917M in 2025, while cash flow improved to positive $74M.
BMI presents a mixed investment case with strong fundamentals offset by legal risks. The stock trades near analyst consensus target of $144.80, offering limited upside. While operational metrics remain healthy, the pending class action and recent earnings volatility warrant caution. Institutional sentiment leans neutral with 55.55% hold ratings, suggesting investors await legal resolution and earnings stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Badger Meter Inc
Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.
Read more on BMI →
